An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial

J Clin Hypertens (Greenwich). 2009 Feb;11(2):89-93. doi: 10.1111/j.1751-7176.2008.00069.x.

Authors

Daniel M Riche¹, Deborah S Minor, Amber S Holdiness, Honey E East

Affiliation

¹ Department of Pharmacy Practice, University of Mississippi, Jackson, MS, USA. driche@sop.umsmed.edu

No abstract available

Publication types

Comparative Study
Review

MeSH terms

Amides / administration & dosage*
Angiotensin II Type 1 Receptor Blockers / administration & dosage
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
Antihypertensive Agents / administration & dosage*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications*
Diabetic Nephropathies / complications
Diabetic Nephropathies / prevention & control*
Drug Therapy, Combination
Evidence-Based Medicine
Fumarates / administration & dosage*
Humans
Hypertension / complications
Hypertension / drug therapy*
Proteinuria / etiology
Proteinuria / prevention & control*
Treatment Outcome

Substances

Amides
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Fumarates
aliskiren